Xenon Pharmaceuticals says XEN1701 surpasses target profile; positive Phase 1 and preclinical data at pain congress

Xenon Pharmaceuticals announced positive Phase 1 and new preclinical data at the IASP 2026 World Congress on Pain, with XEN1701 surpassing its target profile. The data support advancing XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain.

Detected & updated continuously · Source: Nebula